Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.

Abstract: Disclosed is a photovoltaic array structure having low line loss. The photovoltaic array structure includes several photovoltaic modules as photovoltaic array units, where each photovoltaic module includes one photovoltaic cell string or a plurality of photovoltaic cell strings distributed row by row or column by column and connected in series and/or in parallel, and the photovoltaic module includes a long side and a short side, a first end edge junction box and a second end edge junction box being arranged on light-facing surfaces or surfaces facing away from light at two ends along a center line of the long side of the photovoltaic module respectively, and being located on the same side of the long side of the photovoltaic module. The present invention can obviously shorten a thread of a direct current cable in the photovoltaic array structure and reduce line loss inside the photovoltaic array structure.